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CHAPl'ER I

INTRODUCTION
For many years scientists have been searching for
an answer to the problem that the disease leukemia , has
posed.

Numerous drugs have been tested as a possible

check for l eukemia , and one such drug used has been SixMercaptopurine (hereafter referred to as 6-MP) .

6- MP is

a highly toxic nucleic acid antimetabolite that suppresses
antibody formation.

In this form it is a highly effective

immune- suppressant when used against neoplastic conditions
and homografts .

However , it has a high degree of toxicity

which has frequently proved fatal .
The toxicity of 6-MP has limi ted the treatment
period of the drug to approximately two days at a time and
just a little over 1 . 2/mg/kg per day in man as opposed to
1800 mg/kg/day in chicks .

This was observed by Lewis and

others (1968) as a result of research conducted on the toxicity of 6-MP in chicks at Prairie View A. and M. College .
The end- product of protein metabolism in man is
urea, a derivative of 6- thiouric acid as opposed to uric
acid , the end- product of protein metabolism in the chick .
I t has been conclusively established that the chick normally
excretes large amounts of uric acid.

In view of the chick ' s

normal high tolerance for 6 -MP , it seems logical to assume

2

that this species may possess a mechanism which enables
it to normally detoxify the oxidative metabolism endproducts associated with the degradation of 6 -MP and its
derivatives more effectively than man or other species
previously studied .
An understanding of the biochemical mechanism re -

sponsible for the chick ' s capacity to tolerate and efficiently dispose of such agents as 6-MP which are so extremely toxic to man, would contribute significantly to
the information now available for other species .
Since the 6-MP bismuth complex is relatively new
to the field of chemotherapy , it is hoped that this work

will add to the kn.own facts related to its effects in
chemotherapy.
This paper has a twofold purpose s
(1)

To compare the effects of 6- MP and 6-MPBismuth Complex on Leukocyte count .

(2)

To compare the toxicity of 6-MP and 6-MP
Bismuth Complex Ln

50 and Uric acid Concen-

tration of liver and sera.

CHAPTER II
REVIEW OF LITERATURE
The preparation of 6-MP by Elion and others (1952)
initiated the investigation of purine and pyrimidine analogs
as antimetabolites.

The recognition of its clinical value

has led to a large number of biological and bio-chemical
studies.

It is believed that because the structure of 6-MP

closely resembles that of adenine in the purine metabolism
chart described by Harrow (1947) that 6-MP was being oxidized
to Uric acid, just as adenine.
A.

Tumor Inhibition
The activity of 6-MP against sarcoma in mice was

reported to be potentiated by Azarine (Stock and
others, 1955; Clark, 1959).

Martin and others (1958)

reported that a combination of 6-MP and 6-aminocotinamide markedly augmented the curative effects of
X-rays on adenocarcinoma in mice.

The Xanthine

oxidase inhibition (4-hydroxypyrazola (3,4-d)
pyrimidine) (HPP) increased the activity of 6-MP
against adenocarcinoma, but the increase in toxicity
was almost as great (Elion and others, 1962).
B.

Anti-leukemic Action
Six-mercaptopurine is by far the most widely

used purine antagonist which has been useful in
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treating both childhood and adult leukemia.

In

acute granulocytic leukemia, of both childhood and
adult cases, 6-MP induces remission in approximately
10-12 per cent of cases (Burchenal and others, 1953;
Ellison, 1956; Hayhoe, 1955).

c.

Pharmacology
The toxic effects of 6-MP have been described

in detail (Clark and others, 1953; Phillips and
others, 1954).

The Ln

(Single intraperitoneal
50
dose) was about 240 mg/kg in mice and rats. The
mice died between the fifth and fourteenth day after
injection, but the rats began to die as early as the
The Ln
for multiple intraperitoneal
50
injections was 100 mg/kg of body weight per day.

second day.

The toxicity of this purine and its deriviations
has imposed obvious limitations in their use for the
treatment of leukemia.
Due to the recent introduction of the 6-MP bismuth
complex to the field of chemotherapy, no literature was
available concerning it toxicity.
D.

Metabolism
Biological activity of 6-MP was increased by the

simultaneous administration of the xanthine oxidase
inhibition (HPP), at the same time causing a decrease in drug catabolism; thiouric acid and sulfate
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excretion diminished , while the amount of unchanged
drug in the urine increased (Elion and others ,
1962- 63) .
Experiments performed by Hamilton ; Elion , 1954);
Leo and others , (1959) , revealed that 6-thiouric
acid, formed by the action of xanthine oxidase , was
a non- inhibitory metabolite of 6-MP , in man.

Some

of the drug was also converted to inorganic sulfate
(Hamilton and Elion , 1954) .
E.

Mechanism of Action
Six- mercaptopurine has been found to act as an

inhibitor of mitosis in quite low concentration
(Biesele, 1954) and when labeled with radioactive
sulfur is largely incorporated into nucleic acid
(Hamilton and Elion, 1954) .

It appears to produce

its action by competing with inosinic acid on the
pathway to adenylic acid (Hakala and Nichol , 1959) .
It seems that one mechanism by which cells become
resistant to 6-MP is their failure to metabolize
the antagonist to its nucleotide, ribonucleotide
pyrophosphorylase (Brockman , 1960) .

Biesele (1954)

found that coenzyrne A has been most effective in
relieving the mitotic suppression caused by 6-MP.
Brockman and others , (1958) discovered that two
compounds , 6-methoxyaminopurine VII and 2-hydroxyl-

6

amino- 6 - methylthiopurine VI were active against
L1210 mouse leukemia but not against a subline resistant to 6 - mercaptopurine (L1210/6-MP) . The antitumor activity of 6 -MP has been ascribed to its
conversion to an active nucleotide by IMP- CMP
pyrophosphorylase .

Since the 1 1210/6 -MP line is
deficient in this enzyme activity , it is likely
that these two purines are similarly transformed
into active nucleotides by a mechanism analogous

to that of 6-MP.
F.

Clinical Appli cation
The value of 6-MP in the treatment of human

cancer has been discussed in detail by various
authors .

The main application of the drug has been

in acute leukemia in children commonly used with
hormone and antifolic acid treatment {Gunz and
Dameshek , 1959; Sutton , 1962) .
Six-mercaptopurine was found to be largely
effective against most other malignant conditions ,
although , remissi on was seen in a significant number
of patients with lymphosarcoma (White , 1960) .

Its

effectiveness in suppressing immune r esponses has
led to the frequent use of 6-MP in kidney trans planation in man (Calne , 1963) .

CHAP.rER III
METHODS AND MATERIALS
Genetic Stock
Three hundred White Leghorn Cockerels were used as
experimental animals .

The chicks were obtained from Hy- Lay

Hatchery , a commercial enterprise in Bryan, Texas .

The

chicks were obtained on the first day after hatching and
housed in brooders; food (growing mash mix) and water were
provided at libitum at Prairie View A, and M. College .

The

experimental animals were wring- banded on the third day
after hatching and treatment began on the fifth day of age .
Each experiment consisted of seventy-five chicks ,
divided into three groups (Control, 6-MP , 6-MP- Bix) of twentyfive each.

The 6- MP treated chicks received an average

dosage of 900 mg/kg of body weight per day ; 6 -MP- Bix treated
chicks received an average dosage of 1539 mg/kg of body
weight per day, in gelatin capsules (No. 4) by oral adminis tration .
Synthesis of Bismuth Complex
The 6 -MP bismuth complex was synthesized by the
method described bys . Kirshner and others (1966) .

In the

preparation a solution of 1.17 g . of reagent a grade bismuth
(I II) nitrate pentahydrate in 5 ml of concentration HN0

3 and

8

diluted to pH l with water was added to 1 . 28 g . of 6mercaptopurine in 25 ml of 0 . 34N aqueous NaOH.

After the

solutions were mixed , 30 ml of 1N NaOH was added .

The

br ight yellow precipitation formed during this reaction
was filtered , washed consecutively with water , ethanol ,
and ether , and dried in vacuo (vacuum pump system) over
p 2o •
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See Diagram 1 .
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Treatment
Each experiment was conducted over a period of
fifteen days .

The first ten days were designated as " treat-

ment period" with the last five days being considered as
post treatment period .

There were two treated groups of

chicks ; one group receiving 900 mg/kg of body weight/day
of 6-MP and the other group receiving the complex at a level
of 1539 mg/kg of body weight/day.

In actuality both groups

were receiving 6 -MP at a level of 1800 mg/kg of body weight/
day , and the chicks treated wi th the complex were receiving
this drug at a level of 1 . 71 x 1800 mg/kg of body weight
which was equivalent to 3078 mg/kg/day.
The chicks were weighed individually each day of
treatment .

Average weight were calculated and capsules

weighed on the analytical balance to ensure accuracy in
measuring the correct amount of drug in each capsule .

The

capsules were dipped in glycerin and administered orally
while control group received empty capsules .
Determination of Uric Acid
Uric acid determinations on blood and liver were
made at the following intervals ,

(1) five days after treat-

ment , (2) at Ln
I.

, (3) five days post treatment .
50
A. Principle

The principle of this analysis for serum and
ur ic acid was that of Bittner , 1963 , in which Uric
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acid reduces a copper chelate in an acetic acid
medium , eliminating the customary interference from
other reducing substances which occur a method employing a carbonate medium and resulting in a highly
specific test for Uric acid .

No Cyanide was used .

A trichloreacetic acid filtrate or centrifugate was

added to an alcoholic sodium hydroxide solution to
destroy the reducing abilities of certain sulfhydrol
compounds as Ascorbic acid .

A copper chelate in

acetic acid was then added to the alkaline mixture ,
and ·uric acid reduced the cupric complex of the
indicator in a final acid reduction medium .

A

brilliant yellow-orange color development in less
than ten minutes , and the chromagenic response was
stable for many hours .

The response of chromagen

was linear through at least 20 mg per 100 ml using
the recommended procedure .

The color developed was

read in a colorimeter or spectrophotometer at or
near the wave length of maximum absorption. (454 mu . ) .
B.

Reagents 1
Bittners ' Redox Reagent Solution , 8 oz .

This is an acetic acid solution of 2 , 9-dimethyl-l,
1 Reagents were obtained commercially from Oxford
Laboratories , 273 North Shore Boulevard , Post Office Box
5007 , San Mateo , California 94402 .
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10- phenanthroline which is complexed with cupric
ion.
Alcoholic Sodium Hydroxide , 8 oz .

This is a

mixture of half methyl alcohol and half l . ON sodium
hydroxide .
Uric Acid Standard Solution , 1 oz.

This is an

aqueous , slightly acetic , Uric Acid standard .
Formaldehyde is added as a perser vati ve , and the
pH of the solution is adjusted to 5.5 with glacial
acetic acid.

Although this is packed as a 25 , 0mg-%

Uric Acid solution , it is used as the equivalent of
5 . omg% standard in its final dilution .
Working Uric Acid Standard Solution , to a clean

50 . 0 ml volumetric flask exactly 1.0 ml of Uric
Acid Standard and 25 . 0 ml of

5% trichloroacetic

acid were added , and filled to the mark with dis tilled water.

This solution is allowed to stand

stable in plastic contai ners at room temperature
for several days .
Preparation of Samples
II .

A. Blood
Five chicks per group were sacrificed by de -

capitation for each Uric acid determination. Blood
f r om the cervical vessels was collected by pooling
in centr ifuge tubes swirled with a glass rod to
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mix it thoroughly and allowed to set at room temperature until clotting was completed, then centrifuged twenty minutes at 2300- 2500 rpm.

After

centrifugation , the serum was immediately separated
from all solid material (blood cell , etc . ).

All

solid material was discarded .
B.

Liver

After decapitation and blood samples were taken,
the liver was obtained by excisions .
weighed and frozen .

It was then

Three days later, it was

thawed and homogenized by grinding using a mortar
and pestle and a small amount of sand was added to
assure thorough homogenization .

Water was then

added equivalent to the weight of liver , or the
amount required to obtain a specific dilution
factor,

Centrifugation and separation of serum

from solid material (liver tissue) was identical
to that of blood ,

c.

All solid material was discarded .

Procedure

To 1 . 0 ml of serum , 9, 0 ml of freshly diluted

5% trichloracetic acid (TCA) was added. The pre cipitated protein was allowed to remain in TCA for
fifteen minutes to assume complete precipation
before filtration .
was used ,

Whitman No. 40 filter paper

Five aliquots per group were analyzed
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(that is , 6 -MP , Bi-Complex , and Controls) .
blank

and

One

one standard were also analyzed .

The test tubes were labeled , and reagents were
added as shown,
Unknown
Filtrate

Standard

Blank

1 . 0 ml

Working Standard

1 . 0 ml

5% TCA

0. 5 ml

Water

0 . 5 ml

Alcoholic NAOH

2. 5 ml

2. 5 ml

2. 5 ml

(Tubes were agitated , allowed to stand about four
minutes , and the final reagent was added) .
Bi ttners • Read ox
Reagent

2. 5 ml

2. 5 ml

2. 5 ml

All tubes were mixed and allowed to stand for ten
minutes for complete color development .

The color

was stable as compared to the blank for several hours .
Colormetric readings were made at 454 mu . using a
Bausch and Lomb Spectrophotometer.

III .

A.

Calculations
1.

Dosage of 6 -MP
Dosage Level= wg/capsule/day
avg . wt . (kg)
mg/capsule/day= (avg. wt . (kg) x (mg/kg
of body weight)

15
2.

Dosage of 6-MP-Bix
1 71 Cf
Dosage Level= mg/capsule/day
avg. wt . (kg) x •
• •
or
Dosage Level= 1 . 71 x 1800 x avg . wt . of
chick ,

J.

Uric Acid Determination by Colorimetric
method :
Blood s
0 , D. Unk . x Cone . Std . = Cone . Unk .

o.n. std.
Livers

Correction Factors

15g liver sample x
7 = Total amt . of
liver homogenate
(105 ml)
= Vol . of Homogenate (Liver+ H2 0)
C. F .
wt . of Liver

15g liver sample+ 105 ml of H2o
=
15g.
B,

s.o

Key
0 . D. = optical density
Unk . = Unknown
Std . = standard
Cone . = Concentration
c . F . = Correction factor

C. f . = necessary for
the adjustment
of diluted
liver uric acid
concentration
which was linear
to 20mg-% .

CHAPTER IV
RESULTS
The effect of pure 6 - mercaptopurine (6 -MP) and 6 -MP
complexed with bismuth has been studied in a series of four
experiments designed to determine Leukocyte Suppression and
Uric Acid Synthesis of Sera and Liver in the male White
Leghorn Chicks .
Complexing 6-MP with bismuth appeared to reduce the
acute toxicity of the pure compound as demonstrated by the
comparative mortality and weight depressing effect of the
two compounds at equal dosage levels but it was recognized
that on an equimolar basis , the 6- MP complex was heavier
than pure 6-MP molecule .

Consequently , when equal dose

levels were administered at the first of these experiments ,
chicks receiving the 6-MP complex actually were ingesting
proportionately less , by actual weight, of the active principle in the complex , than those receiving the pure 6-MP.
It was therefore , decided that a correction factor was neces sary and according to the calculations it was found that
1 , 71 would accurately adjust for the difference as stated ,
The Bi- x chicks were treated on a level of J078mg/kg of
body wt,/day (1800xl , 71 = J078mg/kg/day).
Figure 2 illustrates the effect of 6 -MP (1800mg/ke/
day) and Bismuth Complex (3078mg/kg/day) on the growth rate
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of the chicks as compared with the control group.

The five -

day old chicks received the 6 -MP and bismuth complex at
equimolar dosage level for a period of ten days .

The treated

chicks exhi bited a retardation in weight while the controls
continued to grow nonnally.

Bismuth complex treated chicks

exhibited a gai n in weight greater than 6-MP treated chicks
but failed to gain weight equal to that of the controls .
Immediately following cessation of treatment (post- treatment
period) trea ted chicks showed an increase in growth rate .
Figure 3 illustrates the dosage level of the two
drugs that were administered to the chicks during the ten
days of treatment.

The drugs were given orally in gelati n

capsules to the chicks at equimolar l evels 1800mg/kg/day
versus 3078mg/kg/day.
Following a five - day treatment period , Uric acid
concentration for serum was found to be 7 , 13to .15 ; 10 . 6st
0 . 12 ; 6.01t5 . omg per 100 ml for control , 6-MP , and 6-MP
bismuth- treated group, respectively.

It was not until the

end of the treatment period (10 - days) that any significant
differences were apparent between the uric acid values ,
7 . 45±0 . 27 ; 13. 24t 1 . 27 ; 6 , 07±0. 54 mg per 100 ml (P=0 , 05) for
the respective groups mentioned above .
It was found that at the end of the fifth day of
treatment , the uri c acid values of the liver were 106 . 57±
1 , 07 ; 127 . 6oto . 70 ; 69. 17±57 mg per 100 ml of liver homogenate
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for controls , 6 -MP and 6-MP bismuth complex groups , respec t i vely.

There was a significant difference between the

value for the contr ols and 6-MP bismuth complex group;
P=0 . 05 .

Significant differences between the controls and

6-MP treated chicks was not evident until the end of the
tenth day of t r eatment; P=0 . 05 .

Figures 4 and 5 show the

effects of 6-MP and the bismuth complex on serum and liver
Uric acid concentration after five and ten days of treatment ,
respectively.
The effect of 6-MP and its bismuth complex on leukocyte count at equal (1800mg/kg body wt . ) and equimolar
(1800 versus 3078 mg/kg body wt/day) levels resulting from
the series of experiments is shown in Figures 7 and 8 re spectively.

Figure 6 shows the treatment of five day old

chicks with pure 6-MP caused a marked decrease in the average
leukocyte count from 33 , 000 to 23 , 000 in contrast to an
average of 26 , 000 observed after five days of drug adminis tration for the chicks treated the bismuth complex .

Signi -

ficant reductions in the leukocyte counts of chicks in groups
treated with 6-MP were observed at the end of the five - day
and ten- day treatment periods (Figure 6) , P=0 . 01 .

The

leukocyte- suppressive effect of 6 -MP was significantly greater than that of its bismuth counterpart at the end of five day treatment period (Figure 6) .

After five days of treat-

ment with bismuth complex , no significant change occurred

20

in the leukocyte count .

However, after ten days of treat-

ment a s i gnificant decrease was evident .
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CHAPTER V
DISCUSSION
The effect of six- mercaptopurine (6 -MP) and its
bismuth complex on Leukocyte Suppression and on Sera and
Liver Uric Acid values in young chicks was determined
utilizing five- day- old white Leghorn cockerels treated with
6-MP and the bismuth complex of this immunosuppressant at
equimolar dosage levels (1800 and 3078 mg/kg/day , respectively) for a ten-day period .

The drugs were administered

orally and toxicity studies were based on macroscopic
manifestations.

Uric acid concentration were determined

by colormetric analysis of the blood and liver.
Figure 2 illustrates the growth rate of the chicks
which show the effect of the two compounds .

The delay in

weight increase as compared with that of the controls observed in this experimentation confirms the postulation
of Goodhart (1955) .

It has been stated that antimetabolites

are compounds which are antagonistic to metabolites of
physiological importance .

More specifically , an antimeta-

bolite is sufficiently similar in structure to an essential
metabolite which tends to replace it in the biological sys tem, thus causing a conditioned deficiency of the metabolite ' s
normal growth.

This relationship between weight gain sup-

pression and toxicity is supported by Wooley (1947), who
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reported that antagonists (antimetabolites) are competitive
with the naturally occurring phenomenon, competing for
essential enzyme systems with which the metabolite normally
reacts .

The property of inactivating enzyme systems is

common among cellular poisons .
Effect .2ll Uric Acid Synthesis
A.

Serum
Following a five-day treatment period, Uric acid

concentration were to be 7 . 13±0 . 15 ; 10 . 68±0 . 12 ; 6 . 01±5. 0 mg
per 100 ml for control , 6 -MP , and 6 -MP- Bi smuth treated
groups , respectively .

No significant difference between

the values were observed at this time .

It was not until

the end of the treatment period (ten- days) that any significant differences were apparent between the Uric acid
values, 7 . 45±0 . 27; 13. 24±1. 27; 6 . 07±0.54 mg per 100 ml
(P = 0 . 05) for the respective group already mentioned .

The

compared values 9. 20±5. 07; 5 . 74±7 . 2 mg per 100 ml for the
controls and 6-MP bismuth complex treated chicks , respec tively , were found to be non-significant .
B.

Liver
It was found that at the end of the fifth day of

t r eatment , the Uric acid values were 106 . 57±1. 07; 127. 60±
0 . 70; 60 . 17±57 mg per 100 ml of liver homogenate for controls , 6 - MP and 6-MP- bismuth complex groups , respectively.
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There was a significant difference between the value for
the controls and 6-MP- bismuth complex group ; P = 0 . 05.
Significant differences between the controls and 6-MP treat ed chicks were not evident until the end of the tenth day
of treatment; P = 0 . 05 .

The Uric acid values were 104 . 3t

0 . 4J ; 114.1t5.37; 63 . 35t1. 3 mg per 100 ml for controls,
6-MP, and 6-MP- bismuth-treated chicks at this time.

Five

days after cessation of treatment (post-treatment period)
the Uric acid values were found to be 8o . 42t5.7; 93.3ot
9. 1; ?4. 35t7.93 mg per 100 ml for the respective groups.
No significant difference was found between these values .
Figures 5 and 6 show the effect of 6-MP and the bismuth
complex on serum and liver after five and ten days of treat ment.

This suggests that since the liver is the site for

the synthesis of uric acid , which is readily conveyed to
the excretory organs via the blood, an increase in serum
acid concentration is logical at an early stage of treatment .

The results obtained with the chicks substantiate

the findings of other investigations.

According to Gerbrandy

(1958); Sanberg and others (1956); Krakoff and others
(1961) ; and Walkins and Silver,(1958), very large quanities
of uric acid are excreted during treatment of leukemia
with X- rays , steriods and antimetabolites .

Krakoff and

others (1961) stated that not all antimetabolites will cause
a rise in uric acid excretion; folic acid antagonists block
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purine synthes i s at a stage prior to that of Uric acid
formation and their administration is followed by a fall
rather than a rise in urinary uric acid .

Uric acid ana-

lyses of the serum and liver five days post treatment ,
showed no significant differences between controls and
treated chicks .
Leukopenia Induction Capacity
Leukocyte Suppression
Traditionally, chemotherapeutic agents such as
6-MP have been used empirically in the treatment of leukemia because they have been well established and found
to depress the leukocyte count of experimental animals .
The leukocyte induction capacity of 6 -MP has been well
established , both experimentally and clinically.

Numerous

investigators have reported on the effectiveness of 6 -MP
as a leukopenia induction agent in experimental mammals
(Elion and others , 1951- 1954) .

The clinical evaluation

of this compound was initially reported (Burcheral and
others , 1953) and subsequently confirmed by many other
investigators .
The results of this experimentation have confirmed the work reported in previous studies (Lewis and others ,

1968) which demonstrated that 6 -MP and its platinum complex
were effective leukopenia-induction agents in the chicks .
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According to results , it appears that the bismuth complex
was as effective in its ability to induce leukopenia as
6 -MP and its platinum and palladium complexes .

The reduced

toxicity of bismuth complex wa s apparent as well demonstrated by comparative weight gain and the lesser degree of
mortality exhibi ted by the chicks treated with the complex .
These findings should be confirmed by further study
with other species in which leukemia has been experimentally induced .

Such complexed agents as 6 -MP bismuth may

have potential clinical utility in the prolonged treatment
of leukemia , a procedure which has thus far been complicated
by the extreme toxicity of 6 - MP .

CHAPTER VI
SUMMARY AND CONCLUSIONS
An investigation designed to determine the effects
of 6-MP and 6-MP bismuth complex on Leukocyte Suppression
and uric acid synthesis of the sera and liver in the chick
has been conducted .

Five day old white Leghorn Cockerels

were treated with two drugs by oral administration daily
at levels of 1800 mg/kg (6-MP) and 3078 mg/kg of the bis muth complex .
The toxicity effects manifested as a result of the
administration of the drugs were determined macroscopically.
These toxic effects observed in the 6-MP treated chicks
were s

weight suppression , hepatic necrosis , gastrointes-

tinal disturbances (congestion , lesions in epithelial
lining) and high mortality rate .

Determinations made by

colorimetric analyses were increased uric acid concentration in the blood and liver.

The manifestation for the

bismuth complex treated chicks were similar but not as
severe.

Very little toxic effect , nor increased uric acid

concentration were observed after the first five day treatment period ;

but after ten days of treatment , most severe

toxic effects were observed and uric acid concentration
of the blood and liver were high for both treated groups .
Also the results of the uric acid values obtained in this
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investigation showed that the 6 -MP bismuth-treated chicks
produced less uric acid than the 6-MP treated group.

It

is highly possible that the complex caused a fall in uric
acid concentration by the mechanism postulated by Krakoff
and co-workers .
At the end of the fifth day of treatment period ,
6-MP capacity to reduce the leukocyte count was more
effective than its counterpart, bismuth complex.

However ,

at the end of the tenth- day- treatment period , the bismuth
complex capacity to reduce the leukocyte count was much
greater than the 6-MP.

The Bismuth Complex was less toxic,

as evidenced by greater weight gain , lower mortality , and
LD
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determinations .
The following conclusions have been drawn on the

basis of this investigation s
(1)

Chicks treated on the level of 1800 mg/kg of

6-MP/day show a high degree of toxicity after tenth day of
treatment .
(2)

Chicks treated on the level of 3078 mg/kg of

Bismuth- X/day showed a lesser degree of toxicity for the
same treatment period as 6 - MP chicks .

(3)

Six-MP has the ability to reduce the leukocyte

count of the chick in ten-day treatment period.

(4)

Bi - X has the ability to reduce the leukocyte

count of the chick in ten-day treatment period but reduces
the count greater than 6-MP at the end of the ten- day treatment period.
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(5)

There is a direct relationship between uric

acid and toxicity.

(6)

The index of purine toxicity may be determined

by uric acid concentration .

(7)

Bi - X may have clinical applications in the

treatment of gout and allergic encephalomyelitis , since it
suppresses the uric acid content of the blood and liver
lower than that of controls and reduces the leukocyte count
lower than 6-MP.
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